BFM
CABA icon

Boothbay Fund Management’s Cabaletta Bio CABA Stock Holding History

Boothbay Fund Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-58,200
Closed -$993K – 1549
2024
Q1 		$993K Buy
58,200
+10,300
+22% +$221K 0.02% 760
2023
Q4 		$1.09M Buy
+47,900
New +$805K 0.03% 701

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boothbay Fund Management's CABA Position: Q2 2026 in Review

Boothbay Fund Management reduced its Cabaletta Bio (CABA) stake by 25% in Q2 2026, selling an estimated $201K and leaving 182,455 shares worth $567K. The position accounts for 0.01% of the portfolio, ranked #1414.

Boothbay Fund Management first reported a position in CABA in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.46M in Q3 2021. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Boothbay Fund Management held 182,455 shares of Cabaletta Bio worth $567K as of Q2 2026.
  • Boothbay Fund Management sold 60,990 Cabaletta Bio shares in Q2 2026, an estimated $201K.
  • Cabaletta Bio made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1414 holding.
  • Boothbay Fund Management first reported a position in Cabaletta Bio in Q1 2021 and has held it in 14 quarters since.
  • Boothbay Fund Management's Cabaletta Bio position peaked at $1.46M in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.